• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Better Therapeutics Inc.

    5/23/24 2:28:26 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTTX alert in real time by email
    POS AM 1 d837673dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on May 23, 2024.

    Registration No. 333-261383

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 3 TO:

    Form S-1 Registration No. 333-261383, as amended by

    Post-Effective Amendment No. 1

    and by Post-Effective Amendment No. 2 on Form S-3

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    BETTER THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   2834   85-3472546

    (State or other jurisdiction

    of incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification Number)

    548 Market Street, #49404

    San Francisco, CA 94104

    (415) 887-2311

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Craig R. Jalbert

    548 Market Street, #49404

    San Francisco, CA 94104

    (415) 887-2311

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Sam Zucker, Esq.

    Shoaib Ghias, Esq.

    Goodwin Procter LLP

    Three Embarcadero Center

    San Francisco, CA 94111

    (415) 733-6000

     

     

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statement.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 3 relates to the following Registration Statement (the “Registration Statement”), filed with the Securities Exchange Commission (the “SEC”) by Better Therapeutics, Inc. (the “Registrant”):

     

      •  

    Registration Statement No. 333-261383 on Form S-1, originally filed with the SEC on November  29, 2021, as amended by the Post-Effective Amendment No. 1 on April  1, 2022, and Post-Effective Amendment No. 2 on Form S-3 on March 31, 2023.

    The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold under the Registration Statement as of the date hereof. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment to the Registration Statement and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on May 23, 2024.

     

    BETTER THERAPEUTICS, INC.
    By:  

    /s/ Craig R. Jalbert

      Craig R. Jalbert, Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.

    Get the next $BTTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTTX

    DatePrice TargetRatingAnalyst
    11/24/2021$17.00Buy
    Chardan Capital Markets
    11/10/2021Outperform
    Cowen
    More analyst ratings

    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

      Better Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq's continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be d

      3/14/24 9:38:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

      One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

      3/5/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians

      3/4/24 9:25:00 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care